广泛导管内成分与保乳术后局部复发风险评估

保乳手术已成为早期乳腺癌的主要治疗手段,评估其局部复发的首选指标为广泛导管内成分(EIC).许多研究证实,EIC阳性者局部复发率较高,但远期生存率并不明显低于阴性者.除了病理检查之外,钼靶X线对检出EIC也有较高的参考作用.从分子生物学角度看,EIC与染色体1q21-23区域的等位基因缺失、cerbB-2过表达等因素正相关,而与p53的过度表达、细胞凋亡没有明显关系.EIC的检测对于早期乳腺癌的综合治疗方案选择具有重要指导意义.

EIC and the risk of local recurrence after breast-conserving therapy on breast cancer

Breast-conserving treatment has become one of the standard therapies for early breast cancer. Extensive intraduct component (EIC) in invasive duct carcinoma is one of the main factors affecting local cancer recurrence and thereby a major consideration in breast conserving therapy. As many researches proved, the higher the degree of EIC, the higher the risk of local recurrence, but the presence of EIC had no influence on overall survival. Beside pathology method, the value of mammographic findings at predicting the presence of EIC is important also. By molecular biological research, there is positive correlation between EIC ( + ) and allelic loss in region 1q21-23, or overexpression of cerbB-2. On the other hand, there is no prominent correlation between EIC ( + ) and overexpression of p53, or apoptosis. In short, EIC is an important indicator for the choice of combined therapeutic regimen for early breast cancer.